Citigroup Inc Theravance Biopharma, Inc. Transaction History

Citigroup Inc

$169 Billion
Q3 2024

A detailed history of Citigroup Inc transactions in Theravance Biopharma, Inc. stock. As of the latest transaction made, Citigroup Inc holds 29,089 shares of TBPH stock, worth $275,472. This represents 0.0% of its overall portfolio holdings.

Number of Shares

29,089

Previous 14,888 95.39%

Holding current value

$275,472

Previous $126,000 85.71%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$7.66 - $10.25 $108,779 - $145,560	14,201 Added 95.39%	29,089 $234,000
Q2 2024 Aug 12, 2024	SELL	$8.29 - $9.92 $88,860 - $106,332	-10,719 Reduced 41.86%	14,888 $126,000
Q1 2024 May 10, 2024	BUY	$8.22 - $11.59 $89,326 - $125,948	10,867 Added 73.72%	25,607 $229,000
Q4 2023 Feb 09, 2024	BUY	$8.58 - $11.4 $78,601 - $104,435	9,161 Added 164.21%	14,740 $165,000
Q3 2023 Nov 09, 2023	SELL	$8.38 - $10.44 $159,672 - $198,923	-19,054 Reduced 77.35%	5,579 $48,000
Q2 2023 Aug 10, 2023	BUY	$10.16 - $11.92 $178,663 - $209,613	17,585 Added 249.5%	24,633 $254,000
Q1 2023 May 11, 2023	SELL	$9.87 - $11.44 $9,583 - $11,108	-971 Reduced 12.11%	7,048 $76,000
Q4 2022 Feb 09, 2023	SELL	$9.65 - $11.34 $35,193 - $41,356	-3,647 Reduced 31.26%	8,019 $89,000
Q3 2022 Nov 10, 2022	SELL	$8.39 - $10.22 $52,303 - $63,711	-6,234 Reduced 34.83%	11,666 $118,000
Q2 2022 Aug 10, 2022	SELL	$8.41 - $10.34 $22,639 - $27,835	-2,692 Reduced 13.07%	17,900 $162,000
Q1 2022 May 12, 2022	BUY	$8.33 - $12.96 $991 - $1,542	119 Added 0.58%	20,592 $197,000
Q4 2021 Feb 10, 2022	SELL	$7.42 - $11.05 $119,588 - $178,092	-16,117 Reduced 44.05%	20,473 $226,000
Q3 2021 Nov 10, 2021	BUY	$6.77 - $14.41 $247,714 - $527,261	36,590 New	36,590 $271,000

Others Institutions Holding TBPH

# of Institutions

122

Shares Held

47.3M

Call Options Held

200

Put Options Held

12.8K

View Full List

About Theravance Biopharma, Inc.

Ticker TBPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 66,782,400
Market Cap $632M
Description
Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also inc...

More about TBPH

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account